Choosing Between First-Line Treatment Options for Relapsed or Stage IV Clear Cell Renal Cell Carcinoma (RCC)

We will discuss the current FDA-approved first-line NCCN Category 1 treatment options for relapsed or stage IV clear cell RCC, specifically evaluating the various immunotherapy (IO) combination therapies, their clinical application, and considerations for choosing between available combinations. We will also review the side effect/toxicity profile and management strategies for each therapy.   The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.